0
Obstructive Lung Diseases |

Clinical Differences Between Patients With COPD Due to Biomass Smoke or Tobacco FREE TO VIEW

Pilar Sanjuán, MD; Rafael Golpe, PhD; Luis Pérez-de-LLano, PhD; Esteban Cano, MD; Olalla Castro-Añon, MD
Author and Funding Information

Hospital Universitario Lucus Augusti, Lugo, Spain


Chest. 2014;145(3_MeetingAbstracts):421A. doi:10.1378/chest.1808632
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD II

SESSION TYPE: Slide Presentations

PRESENTED ON: Monday, March 24, 2014 at 09:00 AM - 10:00 AM

PURPOSE: Biomass smoke exposure is a risk factor for developing chronic obstructive pulmonary disease (COPD). Little is currently known concerning clinical differences between COPD due to tobacco and to biomass smoke. The purpose of this study was to search for clinical differences between both types of disease

METHODS: Retrospective observational study of 499 patients diagnosed of COPD due to tobacco or to biomass smoke exposure. Both groups were compared regarding the prevalence of several predefined clinical phenotypes, severity of the disease measured using several markers, and weight of comorbidities assessed using the Charlson and the COTE indices

RESULTS: Three hundred and seventy seven patients (75.5%) were included in the tobacco group and 122 (24.4%) in the biomass group. There were more males in the tobacco group (91.2% vs 41.8%, p < 0.0001) and patients were younger in this group (70.6 vs 76.2 years, p < 0.0001). More patients were classified in GOLD B stage (29.5% vs 13.5%, p = 0.0001) and less in GOLD D stage (32.8% vs 46.4%, p = 0.01) in the biomass group than in the tobacco group. BODEX values were lower in the biomass group. The COPD-plus-asthma phenotype was more prevalent in the biomass group (21.3% vs 5%, p < 0.0001), although this difference disappeared on adjustment for sex. The emphysema phenotype was more frequent in the tobacco group (45.9% vs 31.9%, p = 0.009). The chronic bronchitis and frequent exacerbator phenotypes were similarly distributed between both groups. The weight of comorbidities and the rate of hospital admissions were also similar between the biomass and tobacco groups

CONCLUSIONS: There are several clinical differences between patients with COPD due to tobacco and to biomass smoke exposure, although some of them might be partially attributable to sex differences between both groups

CLINICAL IMPLICATIONS: The fact that COPD due to biomass smoke has a different clinical presentation suggests that the natural history, the rate of progression and the inflammatory pattern might be different to COPD due to tobacco. This fact might have therapeutic implications. Further studies should be carried out to clarify this point

DISCLOSURE: Pilar Sanjuán: Consultant fee, speaker bureau, advisory committee, etc.: Almirall, Astra-Zeneca, Boehringer-Ingelheim Rafael Golpe: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, GSK, Astra-Zeneca, Boehringer-Ingelheim, Almirall Luis Pérez-de-LLano: Grant monies (from industry related sources): Almirall, Consultant fee, speaker bureau, advisory committee, etc.: Almirall, Novertis, Astra-Zeneca, Boehringer-Ingelheim, GSK, Menarini Esteban Cano: Consultant fee, speaker bureau, advisory committee, etc.: GSK Olalla Castro-Añon: Consultant fee, speaker bureau, advisory committee, etc.: Novartis

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543